New hope for rare fat disorder: safety trial launches for olezarsen
NCT ID NCT05185843
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests the safety of a new drug called olezarsen in 24 people with familial chylomicronemia syndrome (FCS), a rare condition that causes extremely high blood fats. Participants have already been treated with a similar drug, volanesorsen. The study monitors for side effects like low platelet counts and kidney issues, and also checks how well the drug lowers blood fats.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ARC Biosystems, Clinical Assessment Unit (CAU)
Vancouver, British Columbia, V6Z 2C7, Canada
-
Centre Hospitalier Universite de Sherbrooke (CHUS)
Sherbrooke, Quebec, J1H 5N4, Canada
-
Centre for Heart Lung Innovation
Vancouver, British Columbia, V6Z 1Y6, Canada
-
Clinique des Maladies Lipidiques de Quebec Inc.
Québec, Quebec, G1V 4W2, Canada
-
Diabetes/Lipid Management & Research Center
Huntington Beach, California, 92648, United States
-
Ecogene-21
Chicoutimi, Quebec, G7H 7K9, Canada
-
Excel Medical Clinical Trials, LLC
Boca Raton, Florida, 33434, United States
-
Karolinska University Hospital Huddinge
Stockholm, 171 77, Sweden
-
St. Boniface General Hospital
Winnipeg, Manitoba, R2H 2Ab, Canada
-
University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND)
Ann Arbor, Michigan, 48109-2800, United States
-
University of Rochester School of Medicine
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.